In vitro, the MUC16/CA125 refractory NAV-001-PNU was found to be more effective against MUC16/CA125 HIO-positive tumor cell lines in contrast to another MSLN-PNU ADC (SS1-PNU) that was bound by MUC16/CA125. The gene discussed is MUC16; the disease is neoplasm.